Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus CHOLOVUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus CHOLOVUE.
CHOLETEC vs CHOLOVUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Complexes with anions in the gastrointestinal tract to increase fecal elimination of iodipamide, reducing systemic absorption and enhancing gallbladder visualization.
1 gram intravenously every 8 hours; maximum 3 g/day.
100 mg/kg intravenously over 30 minutes every 3-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
Terminal elimination half-life is 6–8 hours in patients with normal renal function; prolonged to 15–20 hours in moderate renal impairment (CrCl 30–50 mL/min) and >24 hours in severe renal failure.
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Primarily renal; approximately 70% excreted unchanged in urine within 24 hours, with the remainder eliminated as glucuronide conjugates via biliary/fecal route (20%) and minor metabolic pathways (10%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent